Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (DE:GBMB)
FRANKFURT:GBMB
RESEARCH TOOLSreports
Inovio Pharmaceuticals (GBMB) Stock Price & Analysis
0 Followers
GBMB Stock Chart & Stats
Day’s Range€0.54 - €0.55
52-Week Range― - ―
Previous Close€6.25
Volume0.00
Average Volume (3M)N/A
Market Cap
$129.01M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Mar 13, 2024EPS Estimate
-€1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.66Price Target Upside200.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Inovio Pharmaceuticals News
GBMB FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Inovio Pharmaceuticals’s market cap?
Currently, no data Available
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Mar 13, 2024 which is 48 days ago.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Nov 09, 2023. The company reported -€1.439 earnings per share for the quarter, missing the consensus estimate of -€1.402 by -€0.037.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -€1.14.
How many shares outstanding does Inovio Pharmaceuticals have?
Currently, no data Available
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -€1.439 in its last earnings report, missing expectations of -€1.402. Following the earnings report the stock price went up 10.429%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Among the largest hedge funds holding Inovio Pharmaceuticals’s share is GMT Capital Corp. It holds Inovio Pharmaceuticals’s shares valued at 589K.
---
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.66 (200.69% Upside)
€1.66 (200.69% Upside)
Blogger Sentiment
Neutral
DE:GBMB Sentiment 50%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-69.12%
12-Months-Change
Fundamentals
Return on Equity
-81.30%
Trailing 12-Months
Asset Growth
-50.74%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
---
GBMB Earnings Call
Q3 2023
0:00 / 0:00
---
GBMB Stock 12 Months Forecast
Average Price Target
€1.66
▲(200.69% Upside)
Technical Analysis
Best Analysts Covering GBMB
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-60.77%
upgraded a buy rating 3 months ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -60.77% per trade.
---